GSK Says Paper Published In Nature Medicine By Company Scientists To Be Retracted
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK confirms dismissal of R&D China Head Jingwu Zang. GSK internal communication seen by PharmAsia News alleges “disturbing efforts” by employees to undermine an internal investigation into a paper on preclinical research; GSK suspends programs related to IL-7 receptor signaling pathway.
You may also be interested in...
GSK Jumps Into Growing China R&D Space
GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.